Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cariporide SCHEMBL31563713 | 1.00 | SLC9A1 (1.00) | SLC9A1SLC9A2 | |
| Cariporide SCHEMBL8743795 | 0.99 | SLC9A1 (0.97) | SLC9A1SLC9A2 | |
| Cariporide SCHEMBL611696 | 0.97 | SLC9A1 (1.00) | SLC9A1SLC9A2 | |
| Hydrochloric Acid SCHEMBL8816755 | 0.87 | SLC9A1 (0.78) | SLC9A1SLC9A2 | |
| SCHEMBL8573607 | 0.87 | SLC9A1 (0.78) | SLC9A1SLC9A2 | |
| SCHEMBL8743809 | 0.87 | SLC9A1 (0.76) | SLC9A1SLC9A2 | |
| Hydrochloric Acid SCHEMBL8743818 | 0.85 | SLC9A1 (0.74) | SLC9A1SLC9A2 | |
| SCHEMBL7798624 | 0.85 | SLC9A1 (0.74) | SLC9A1SLC9A2 | |
| SCHEMBL8647605 | 0.84 | SLC9A1 (0.72) | SLC9A1SLC9A2 | |
| SCHEMBL4355373 | 0.83 | SLC9A1 (0.72) | SLC9A1SLC9A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1146863-B1 | LYOPHILISATES WITH IMPROVED RECONSTITUTIBILITY | MERCK PATENT GMBH (DE) | 2004-05-12 | — | — | EP | claimed |
| CN-1367689-A | Use of sodium-hydrogen exchanger inhibitors for producing medicaments for preventing organ dysfunction and diseases caused by aging and for prolonging life | AVENTIS PHARMA GMBH (DE) | 2002-09-04 | — | — | CN | claimed |
| US-6420430-B1 | USE OF BENZOYLGUANIDINE DERIVATIVES TO PREVENT AGING DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-07-16 | — | — | US | claimed |
| EP-1140056-A2 | THE UTILISATION OF INHIBITORS OF THE SODIUM HYDROGEN EXCHANGER FOR PRODUCING A MEDICAMENT FOR PREVENTING ORGAN DYSFUNCTIONS AND DISEASES RELATED TO A PARTICULAR AGE AND FOR PROLONGING LIFE | Aventis Pharma Deutschland GmbH (DE) | 2001-10-10 | — | — | EP | claimed |
| WO-2000038661-A2 | THE UTILISATION OF INHIBITORS OF THE SODIUM HYDROGEN EXCHANGER FOR PRODUCING A MEDICAMENT FOR PREVENTING ORGAN DYSFUNCTIONS AND DISEASES RELATED TO A PARTICULAR AGE AND FOR PROLONGING LIFE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-07-06 | — | — | WO | claimed |
| EP-4709753-A1 | SLC4A4/NBCE1 INHIBITORS | VIB VZW (BE) | 2026-03-18 | — | — | EP | disclosed |
| US-20250262239-A1 | METHOD OF ADMINISTRATION AND TREATMENT | DYVE BIOSCIENCES, INC. | 2025-08-21 | — | — | US | disclosed |
| US-12310983-B2 | Method of administration and treatment | DYVE BIOSCIENCES, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| WO-2024231348-A1 | SLC4A4/NBCE1 INHIBITORS | VIB VZW (BE) | 2024-11-14 | — | — | WO | disclosed |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-4324460-A2 | SODIUM BICARBONATE FOR USE IN THE TREATMENT OF GOUT AND RELATED DISORDERS | Dyve Biosciences, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| US-6844361-B2 | Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-18 | — | — | US | disclosed |
| WO-2003068212-A1 | USE OF SODIUM/HYDROGEN EXCHANGE INHIBITORS FROM THE TREATMENT OF THROMBOTIC AND INFLAMMATORY DISEASES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-08-21 | — | — | WO | disclosed |
| JP-2002105043-A | INTERMEDIATE COMPOUND FOR PRODUCING DIACYL-SUBSTITUTED GUANIDINE | HOECHST AG | 2002-04-10 | — | — | JP | disclosed |
| EP-0918515-A2 | USE OF INHIBITORS OF THE CELLULAR Na?+ /H?+ EXCHANGER (NHE) FOR PREPARING A MEDICAMENT FOR NORMALIZING SERUM LIPIDS | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-06-02 | — | — | EP | disclosed |
| WO-1997046226-A2 | USE OF INHIBITORS OF THE CELLULAR Na+/H+ EXCHANGER (NHE) FOR PREPARING A MEDICAMENT FOR NORMALIZING SERUM LIPIDS | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-12-11 | — | — | WO | disclosed |
| EP-0589336-B1 | Benzoylguanidines, process for their preparation and their use as antiarrhythmic agents | HOECHST AG (DE) | 1997-01-08 | — | — | EP | disclosed |
| US-5591754-A | Benzoylguanidines, pharmaceutical composition containing them and treatment of arrthythmias therewith | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-01-07 | — | — | US | disclosed |
| EP-0589336-A1 | Benzoylguanidines, process for their preparation and their use as antiarrhythmic agents | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | SLC10A1, SLC10A2, FABP3 | SLC9A1 10/4885SLC9A2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.